Eli Lil­ly launch­es PhI­II JAK study, aim­ing for the first drug to low­er mor­tal­i­ty in Covid-19

Soon af­ter the NIH an­nounced in late April that Eli Lil­ly’s JAK in­hibitor baric­i­tinib would be the sec­ond drug test­ed in the tri­al that had proven remde­sivir ef­fec­tive, doc­tors around the world be­gan telling Lil­ly that that wouldn’t be enough.

Since the ear­ly days of the pan­dem­ic, the In­di­anapo­lis phar­ma had heard from doc­tors in Italy, Spain and else­where who, fac­ing hos­pi­tals full of pa­tients with a dis­ease with no known treat­ment, used the JAK in­hibitor — known com­mer­cial­ly as the rheuma­toid arthri­tis drug  Olu­mi­ant — off-la­bel. The doc­tors want­ed to know con­clu­sive­ly if it worked. But the NIH tri­al could on­ly tell them if, when com­bined with remde­sivir, it worked bet­ter than remde­sivir alone. And then on­ly in the more se­vere pa­tients.

Pa­trik Jon­s­son

“We de­cid­ed it’s our oblig­a­tion,” Eli Lil­ly Bio-Med­i­cines Pres­i­dent Pa­trik Jon­s­son told End­points News. “For sci­en­tif­ic rea­sons but most im­por­tant­ly for health­care providers and for pa­tients, we need­ed to un­der­stand the over­all ef­fects of Olu­mi­ant/baric­i­tinib alone in treat­ing Covid-19.”

Lil­ly is now launch­ing their own Phase III, 400-per­son study to test whether baric­i­tinib alone can beat place­bo in treat­ing Covid-19. Spread across 15 sites in 4 coun­tries, the tri­al will test the idea that the drug not on­ly has po­ten­tial to man­age the cy­tokine storms that af­flict late-stage pa­tients, but al­so treat the dis­ease in its mild to mod­er­ate man­i­fes­ta­tions.

Un­like some oth­er ma­jor Covid-19 tri­als, in­clud­ing most no­tably the first part of the NIH study and sev­er­al Gilead ran on remde­sivir, the tri­al’s pri­ma­ry end­point won’t be about time to re­cov­ery or how symp­toms im­prove on an 8-point scale. In­stead, the ques­tion will be sim­ple: At day 28, is there a sig­nif­i­cant­ly few­er num­ber of pa­tients on the drug arm who have died or gone to ven­ti­la­tion than in the place­bo arm?

“Since the com­mu­ni­ty got the da­ta on remde­sivir in the be­gin­ning of May, we are set­ting the bar high­er,” Jonn­son said. “We need to add in­cre­men­tal val­ue.”

The new Lil­ly tri­al joins a throw-any­thing-against-the-wall now cov­ered in tra­di­tion­al Chi­nese and In­di­an med­i­cines, im­mune block­ers and im­mune boost­ers, an­ti-co­ag­u­lants, and an­tivi­rals of myr­i­ad ori­gins. Clin­i­cal­tri­als.gov now lists 1,211 dif­fer­ent in­ter­ven­tion­al Covid-19 tri­als.

Still, re­searchers say there’s rea­son to be­lieve that baric­i­tinib has bet­ter odds than oth­ers. It was first iden­ti­fied as a po­ten­tial treat­ment in Feb­ru­ary by the British biotech Benev­o­lent AI as part of a ma­chine learn­ing-based drug screen.

Vin­cent Mar­coni

“Baric­i­tinib, be­ing a JAK in­hibitor, has some ad­van­tages on some of the oth­er cy­tokine agents,” Vin­cent Mar­coni, an in­fec­tious dis­ease spe­cial­ist at Emory Uni­ver­si­ty, told End­points.

Like the Roche drug IL-6 block­ing drug Actem­ra — which has shown po­ten­tial in ear­ly stud­ies — baric­i­tinib blocks some of the cy­tokines, or im­mune sig­nals, that can lead to an over­ac­tive in­flam­ma­to­ry re­sponse in some pa­tients. But un­like IL-6 block­ers, Mar­coni said, baric­i­tinib blocks sev­er­al im­mune path­ways as op­posed to just one.

“The hope with a sin­gle cy­tokine ther­a­py is that maybe you can get the crit­i­cal one and that’s all that’s need­ed, and the oth­er ones don’t play much of a role. We don’t know the an­swer to the yet,” Mar­coni said. “But with JAK-STAT in­hibitors like baric­i­tinib, we’re re­al­ly tar­get­ing mul­ti­ple of these cy­tokine path­ways. I think that’s one of the main at­trac­tive ra­tio­nales.”

With virus-neu­tral­iz­ing an­ti­bod­ies now en­ter­ing hu­man test­ing — in­clud­ing two from Eli Lil­ly — to great med­ical at­ten­tion, Mar­coni said he could imag­ine a fu­ture where sev­er­al of the most ef­fec­tive ther­a­pies were used in com­bi­na­tion, as in HIV treat­ments.

Any coro­n­avirus study will fluc­tu­ate with the case counts in tri­al site cities, but Lil­ly is hop­ing to have re­sults by Sep­tem­ber. The NIH hasn’t an­nounced a time­line, but the com­pa­ny said it is al­ready more than half-en­rolled.

Pa­tients in the tri­al will still be able to take remde­sivir if their doc­tors pre­scribe it, al­though pa­tients would not nec­es­sar­i­ly fit cri­te­ria for both, said Patrick Mil­li­gan, an in­fec­tious dis­ease spe­cial­ist at the Com­mu­ni­ty Health Net­work in In­di­anapo­lis, one of the study sites. Al­though guid­ance for remde­sivir can vary state to state and even hos­pi­tal to hos­pi­tal, it is gen­er­al­ly giv­en to lat­er-stage pa­tients.

Mil­li­gan said his hos­pi­tal has giv­en baric­i­tinib to Covid-19 pa­tients since the ear­ly days of the pan­dem­ic and the pa­tients who re­ceived it seemed to do bet­ter than those that got Actem­ra. But the re­sults were hard to parse; the pa­tients who got Actem­ra were gen­er­al­ly al­ready in worse con­di­tion.

”This is all anec­do­tal. It’s use­ful. If that’s the da­ta you have, that’s fine,” he told End­points. But now they were join­ing the study “to hope­ful­ly help get some de­fin­i­tive an­swers.”

So­cial: Dar­ron Cum­mings, AP Im­ages

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

Op­ti­miz­ing Cell and Gene Ther­a­py De­vel­op­ment and Pro­duc­tion: How Tech­nol­o­gy Providers Like Corn­ing Life Sci­ences are Spurring In­no­va­tion

Remarkable advances in cell and gene therapy over the last decade offer unprecedented therapeutic promise and bring new hope for many patients facing diseases once thought incurable. However, for cell and gene therapies to reach their full potential, researchers, manufacturers, life science companies, and academics will need to work together to solve the significant challenges facing the industry.

David Baker working with a student on their protein design (Jason Mast)

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

SEATTLE — It’s a cloudy Thursday afternoon in mid-July and David Baker is reclining into the futon in his corner office at the University of Washington, arms splayed out like a daytime talk show host as he coaches another one of his postdocs through the slings and arrows of scientific celebrity.

“Be jealous of your time,” he says, before plotting ways of sneaking her out of Zooms. “It’s this horrible cost to science that you’re tied up in some stupid meeting.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pre­sent­ing a live End­points News event: Man­ag­ing a biotech in tur­bu­lent times

Biotech is one of the smartest, best educated industries on the planet. PhDs abound. We’ve had a long enough track record to see a new generation of savvy, experienced execs coming together to run startups.

And in these times, they are being tested as never before.

Biotech is going through quite a rough patch right now. For 2 years, practically anyone with a decent resume and some half-baked ideas on biotech could start a company and get it funded. The pandemic made it easy in many ways to pull off an IPO, with traditional road shows shut down in exchange for a series of quick Zoom meetings. Generalist investors flocked as the numbers raised soared into the stratosphere.

Patty Murray, D-WA (Graeme Sloan/Sipa USA)(Sipa via AP Images)

Sen­ate user fee reau­tho­riza­tion bill omits ac­cel­er­at­ed ap­proval re­forms, shows wide gaps with House ver­sion

The Senate health committee on Tuesday released its first version of the bill to reauthorize all the different FDA user fees. But unlike the House version, there are only a few controversial items in the Senate’s version, which does not address either accelerated approval reforms or clinical trial diversity (as the House did).

While it’s still relatively early in the process of finalizing this legislation (the ultimate statutory deadline is the end of September), the House and Senate, at least initially, appear to be starting off in different corners on what should be included.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.

Warren Buffett, Berkshire Hathaway CEO

Berk­shire Hath­away pulls out of Ab­b­Vie, Bris­tol My­ers Squibb in­vest­ments

It looks like Warren Buffett is sticking to ice cream and railroads for the moment.

The billionaire CEO of Berkshire Hathaway backed out of two major holdings in the pharma industry, Forexlive first reported, including a $410 million investment in AbbVie and a $324.4 million stake in Bristol Myers Squibb.

The move comes after Berkshire abandoned its Teva shares just last quarter, Bloomberg reported.

Amidst R&D reshuf­fle, Ver­tex ex­pands its pres­ence in Boston, aim­ing to be­come num­ber one

Vertex Pharmaceuticals has been one of the buzzier names in the bustling Boston biotech scene, but now the company is looking to vault to number one status — at least in terms of physical footprint.

At a ribbon cutting on Tuesday for its new Jeffrey Leiden Center for Cell and Genetic Therapies at the Boston Seaport, Vertex announced it would embark on a new project: The company will build a 344,000 square foot facility in the seaport to accommodate the company’s growing R&D needs, especially in its cell and gene therapies program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.

Long-ex­pect­ed UK lay­offs im­mi­nent for No­var­tis fol­low­ing sale

Nearly a year ago, more than 200 workers at Novartis’ Grimsby, UK, facility were able to hang on to their jobs after the pharma closed a Switzerland site as a part of its workforce restructuring plan. Now, it looks like those employees’ time is up, as the site has been sold, Grimsby Telegraph reported today.

The manufacturing site has been sold to Humber Industrials, a subsidiary of International Process Plants. None of the current staff members will be working with the new owners, however.

Robert Califf (AP Photo/Manuel Balce Ceneta)

FDA au­tho­rizes boost­er dose of Pfiz­er and BioN­Tech's Covid-19 vac­cine in 5- to 11-year-olds

The latest wave of the pandemic — marked by Omicron and its sub-variants — has seen higher hospitalization rates for young children, health agencies have observed. That’s part of the reason why the FDA is authorizing a booster shot for kids between 5 and 11 years old.

Regulators on Tuesday OK’d a single booster dose of Pfizer and BioNTech’s mRNA vaccine for children who received their primary series with the same vaccine at least five months ago. By Pfizer’s count, that makes more than 8 million 5- to 11-year-olds eligible for another dose.

FDA lob­bies Con­gress over rare dis­ease court rul­ing with wide im­pli­ca­tions

Usually reserved for making decisions on drug applications or enforcing what Congress stipulates, the FDA is now dipping its toe into the wild world of congressional politics as it attempts to fix a major court decision that could have a chilling effect on rare disease R&D.

The case in question from last October saw a US appeals court overturn a prior FDA court win, saying that the agency never should’ve approved a rare disease drug because a previously approved but more expensive drug with the same active ingredient has orphan drug exclusivity barring such an approval.